Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah
by Zacks Equity Research
Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.
The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical
by Zacks Equity Research
JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.
Top Research Reports for JPMorgan, Gilead Sciences & CSX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
by Zacks Equity Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down
by Zacks Equity Research
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
by Zacks Equity Research
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
by Zacks Equity Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
by Zacks Equity Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Should You Buy Gilead (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.75, moving +0.24% from the previous trading session.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
by Zacks Equity Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $62.06 in the latest trading session, marking a +0.7% move from the prior day.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.